MiRNA-15a Mediates Cell Cycle Arrest and Potentiates Apoptosis in Breast Cancer Cells by Targeting Synuclein-γ |
Li, Ping
(Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University)
Xie, Xiao-Bing (Medical Laboratory Center, First Affiliated Hospital, Hunan University of Chinese Medicine) Chen, Qian (Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine) Pang, Guo-Lian (Department of Pathology, First People Hospital of Qujing) Luo, Wan (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Tu, Jian-Cheng (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Zheng, Fang (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Liu, Song-Mei (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Han, Lu (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) Zhang, Jian-Kun (Department of Pathology, First People Hospital of Qujing) Luo, Xian-Yong (Department of Pathology, First People Hospital of Qujing) Zhou, Xin (Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University) |
1 | Ambros V (2001). MicroRNAs: tiny regulators with great potential. Cell, 107, 823-6. DOI ScienceOn |
2 | Bartel DP (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116, 281-97. DOI ScienceOn |
3 | Cai CK, Zhao GY, Tian LY, et al (2012). miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep, 28, 1764-70. |
4 | Chen C, Ridzon DA, Broomer AJ, et al (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, 179. DOI ScienceOn |
5 | Chen Q, Xia HW, Ge XJ, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-6. 과학기술학회마을 DOI |
6 | Cortez MA, Welsh JW, Calin GA (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res, 195, 151-61. DOI |
7 | Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI ScienceOn |
8 | Garzon R, Heaphy CE, Havelange V, et al (2009). MicroRNA 29b functions in acute myeloid leukemia. Blood, 114, 5331-41. DOI ScienceOn |
9 | Guo J, Shou C, Meng L, et al (2007). Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer, 121, 1296-305. DOI |
10 | Harquail J, Benzina S, Robichaud GA (2012). MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Epidemiol Biomarkers Prev, 11, 269-80. |
11 | Huang F, Liu C, Shi YH, et al (2013). MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. Asian Pac J Cancer Prev, 14, 5915-20. 과학기술학회마을 DOI ScienceOn |
12 | Luo Q, Li X, Li J, et al (2013). MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol, 43, 1212-8. |
13 |
Jiang Y, Liu YE, Goldberg ID, et al (2004). A novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor |
14 | Jiang Y, Liu YE, Lu A, et al (2003). Stimulation of estrogen receptor signaling by gamma synuclein. Cancer Res, 63, 3899-903. |
15 | Liu YE, Pu W, Jiang Y, et al (2007). Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma. Oncogene, 26, 2115-25. DOI |
16 | Ng SB, Yan J, Huang G, et al (2011). Dysregulated microRNAs affect pathways and targets of biologic relevance in nasaltype natural killer/T-cell lymphoma. Blood, 118, 4919-29. DOI |
17 |
Paik JH, Jang JY, Jeon YK, et al (2011). MicroRNA-146a Downregulates |
18 | Qin XJ, Ling BX (2012). Proteomic studies in breast cancer (Review). Oncol Lett, 3, 735-43. |
19 | Shenouda SK, Alahari SK (2009). MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev, 28, 369-78. DOI ScienceOn |
20 | Thorsen SB, Obad S, Jensen NF, et al (2012). The therapeutic potential of microRNAs in cancer. Cancer J, 18, 275-84. DOI |
21 | Wang H, Tan G, Dong L, et al (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7, 34210. DOI |
22 | Yu Q, Liu SL, Wang H, et al (2013). miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev, 14, 6569-72. 과학기술학회마을 DOI ScienceOn |
23 | Wei F, Xu J, Tang L, et al (2012). p27 (Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. Cancer Biother Radiopharm, 27, 665-71. |
24 | Wu K, Quan Z, Weng Z, et al (2007). Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treatment, 101, 259-67. DOI |
25 | Yamanaka Y, Tagawa H, Takahashi N, et al (2009). Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood, 114, 3265-75. DOI ScienceOn |
26 | Valencia-Sanchez MA, Liu J, Hannon GJ, et al (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev, 20, 515-24. DOI ScienceOn |
27 | Lian J, Zhang X, Tian H, et al (2009). Altered microRNA expression in patients with non-obstructive zoospermia. Reprod Biol Endocrinol, 7, 13. DOI |
![]() |